PT - JOURNAL ARTICLE AU - Pierre Garneret AU - Etienne Coz AU - Elian Martin AU - Jean-Claude Manuguerra AU - Elodie Brient-Litzler AU - Vincent Enouf AU - Daniel Felipe González Obando AU - Jean-Christophe Olivo-Marin AU - Fabrice Monti AU - Sylvie Van der Werf AU - Jessica Vanhomwegen AU - Patrick Tabeling TI - Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification AID - 10.1101/2020.08.01.20166538 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.01.20166538 4099 - http://medrxiv.org/content/early/2020/08/04/2020.08.01.20166538.short 4100 - http://medrxiv.org/content/early/2020/08/04/2020.08.01.20166538.full AB - In order to respond to the urgent request of massive testing, developed countries perform nucleic acid amplification tests (NAAT) of SARS-CoV-2 in centralized laboratories. Real-time RT - PCR (Reverse transcription - Polymerase Chain Reaction) is used to amplify the viral RNA and enable its detection. Although PCR is 37 years old, it is still considered, without dispute, as the gold standard. PCR is an efficient process, but the complex engineering required for automated RNA extraction and temperature cycling makes it incompatible for use in point of care settings. In the present work, by harnessing progress made in the past two decades in DNA amplification, microfluidics and membrane technologies, we succeeded to create a portable test, in which SARS-CoV-2 RNA is extracted, amplified isothermally by RT - LAMP (Loop-mediated Isothermal Amplification), and detected using intercalating dyes or highly fluorescent probes. Depending on the viral load, the detection takes between twenty minutes and one hour. Using pools of naso-pharyngal clinical samples, we estimated a sensitivity comparable to RT-qPCR (up to a Cycle threshold of 39, equivalent to <0.1 TCID50 per mL) and a 100% specificity, for other human coronaviruses and eight respiratory viruses currently circulating in Europe. We designed and fabricated an easy-to-use portable device called “COVIDISC” to carry out the test at the point of care. The low cost of the materials along with the absence of complex equipment paves the way towards a large dissemination of this device. The perspective of a reliable SARS-CoV-2 point of care detection, highly performing, that would deliver on-site results in less than one hour, with a self-testing potential, opens up a new efficient approach to manage the pandemics.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialreference 2020/08 from Comite de Protection des Personnes Ile de France IV, IRB#00003835Funding StatementThe authors thank ESPCI, CNRS, IPGG platform (ANR-10-EQPX-34), PSL, PSL-VALO, PASTEUR, Carnot Pasteur Maladies Infectieuses program (ANR 11-CARN 017-01), PARIS City, ANR Flash (ANR-20-COVI-000), DIM ELICIT, Fonds de l ESPCI, BETTENCOURT Fondation for their support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples used in this study were collected as part of approved ongoing surveillance conducted by the National Reference Center for Respiratory Viruses (NRC) at Institut Pasteur (WHO reference laboratory providing confirmatory testing for COVID-19). The lab investigations described in this article were carried out in accordance with French Law which does not required a review by an ethics committee for the secondary use of samples collected for healthcare purposes. However, to fulfill editorial requirements, an Ethics waiver (reference 2020/08) has been obtained by the Institut Pasteur from a French Ethics Committee (Comite de Protection des Personnes Ile de France IV, IRB#00003835). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is in the paper